Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

INTRODUCTION: Despite the development of new therapies for advanced prostate cancer, it remains the most common cause of cancer and the second leading cause of cancer death in men. It is critical to develop novel agents for the treatment of prostate cancer, particularly those that target aspects of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Scheinberg, Tahlia, Kench, James, Stockler, Martin, Mahon, Kate L, Sebastian, Lucille, Stricker, Phillip, Joshua, Anthony M, Woo, H, Thanigasalam, Ruban, Ahmadi, Nariman, Centenera, Margaret M, Butler, Lisa M, Horvath, Lisa G
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7045211/
https://ncbi.nlm.nih.gov/pubmed/31988233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-033667
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars